vs
Side-by-side financial comparison of Aterian, Inc. (ATER) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $15.1M, roughly 1.3× Aterian, Inc.). Aterian, Inc. runs the higher net margin — -52.5% vs -90.7%, a 38.2% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -38.5%). Aterian, Inc. produced more free cash flow last quarter ($-1.0M vs $-37.8M).
Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
ATER vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.1M | $19.1M |
| Net Profit | $-7.9M | $-17.4M |
| Gross Margin | 56.1% | — |
| Operating Margin | -51.1% | -186.1% |
| Net Margin | -52.5% | -90.7% |
| Revenue YoY | -38.5% | 740.1% |
| Net Profit YoY | -512.2% | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.1M | — | ||
| Q3 25 | $19.0M | — | ||
| Q2 25 | $19.5M | $19.1M | ||
| Q1 25 | $15.4M | — | ||
| Q4 24 | $24.6M | $12.8M | ||
| Q3 24 | $26.2M | $29.1M | ||
| Q2 24 | $28.0M | — | ||
| Q1 24 | $20.2M | — |
| Q4 25 | $-7.9M | — | ||
| Q3 25 | $-2.3M | — | ||
| Q2 25 | $-4.9M | $-17.4M | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-1.3M | $-92.2M | ||
| Q3 24 | $-1.8M | $-16.6M | ||
| Q2 24 | $-3.6M | — | ||
| Q1 24 | $-5.2M | — |
| Q4 25 | 56.1% | — | ||
| Q3 25 | 56.1% | — | ||
| Q2 25 | 54.3% | — | ||
| Q1 25 | 61.4% | — | ||
| Q4 24 | 63.4% | — | ||
| Q3 24 | 60.3% | — | ||
| Q2 24 | 60.4% | — | ||
| Q1 24 | 65.1% | — |
| Q4 25 | -51.1% | — | ||
| Q3 25 | -10.7% | — | ||
| Q2 25 | -23.1% | -186.1% | ||
| Q1 25 | -24.1% | — | ||
| Q4 24 | -6.5% | -338.5% | ||
| Q3 24 | -6.6% | -85.9% | ||
| Q2 24 | -11.5% | — | ||
| Q1 24 | -26.1% | — |
| Q4 25 | -52.5% | — | ||
| Q3 25 | -12.0% | — | ||
| Q2 25 | -25.0% | -90.7% | ||
| Q1 25 | -25.4% | — | ||
| Q4 24 | -5.3% | -721.7% | ||
| Q3 24 | -6.8% | -57.2% | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -25.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.9M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.2M | $778.5M |
| Total Assets | $29.6M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.9M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $10.5M | $739.2M | ||
| Q1 25 | $14.3M | — | ||
| Q4 24 | $18.0M | $834.2M | ||
| Q3 24 | $16.1M | $422.7M | ||
| Q2 24 | $20.3M | — | ||
| Q1 24 | $17.5M | — |
| Q4 25 | $15.2M | — | ||
| Q3 25 | $22.6M | — | ||
| Q2 25 | $24.3M | $778.5M | ||
| Q1 25 | $27.0M | — | ||
| Q4 24 | $30.0M | $757.5M | ||
| Q3 24 | $30.6M | $378.9M | ||
| Q2 24 | $30.9M | — | ||
| Q1 24 | $33.0M | — |
| Q4 25 | $29.6M | — | ||
| Q3 25 | $40.1M | — | ||
| Q2 25 | $45.4M | $815.1M | ||
| Q1 25 | $49.8M | — | ||
| Q4 24 | $49.5M | $864.6M | ||
| Q3 24 | $52.1M | $439.2M | ||
| Q2 24 | $59.9M | — | ||
| Q1 24 | $55.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.0M | $-37.7M |
| Free Cash FlowOCF − Capex | $-1.0M | $-37.8M |
| FCF MarginFCF / Revenue | -6.9% | -197.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-4.4M | $-37.7M | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-9.0K | $-37.5M | ||
| Q3 24 | $-722.0K | $-12.5M | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $-6.0K | — |
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-4.4M | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $-42.0K | — |
| Q4 25 | -6.9% | — | ||
| Q3 25 | -8.4% | — | ||
| Q2 25 | -22.7% | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | -0.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATER
| Sales Channel Directly To Consumer | $13.1M | 87% |
| Heating Cooling And Air Quality | $2.1M | 14% |
NAMS
Segment breakdown not available.
